Abstract
Methods A cohort of 1190 JIA patients enrolled in the German JIA Enbrel registry has been used for screening. Matching criteria included JIA subtype, gender, disease duration, use of corticosteroids, oligoversus polyarthritis at therapy start and the sedimentation rate. Efficacy was determined using the PedACR 30/ 50 and 70 response criteria. Safety assessments were based on adverse events reports. The matched data at month 1, 3, 6, 12, 18 and 24 on treatment have been analyzed using the McNemar’s test.
Highlights
No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
Etanercept has been approved in polyarticular juvenile idiopathic arthritis (JIA) patients refractory or intolerant to methotrexate
No infectious serious adverse events occurred in the mono therapy group compared to 3 in the combination group
Summary
From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. 2-5 June 2011. From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. Purpose Etanercept has been approved in polyarticular juvenile idiopathic arthritis (JIA) patients refractory or intolerant to methotrexate. The objectives of the study were to evaluate safety and efficacy of Etanercept and Methotrexate combination therapy versus Etanercept mono therapy in JIA using a matched pair analysis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
